Davos covid dystopia: at 2018 Schwabian event Pfizer CEO Bourla says microchip will be in medication

At Klaus Schwab's annual confab in Davos Switzerland, in a 2018 roundtable interview session Pfizer CEO Albert Bourla [0] stated in no uncertain terms how his ideal future would unfold with the electronic pill as centrepiece.

By then, the FDA had already approved a "tracking device" [1] that can warn patients (or their nurses) if they have failed to ingest their medication.

Bourla noted that the compliance of the patient could thereby be assured. So we see that the miniaturization that is possible with the microchip has already been applied profitably to the human being, with schizophrenic patients as guinea pigs.

The FDA press release indicates that the technology is marketed by Proteus Digital Health [1] of Redwood City CA [2]. Proteus has managed to grow a forest of patents around its RFID pill, which uses "a battery that is activated upon being exposed to fluid in the body".

While the first FDA approval of a particular application of this technology occurred in 2017, the regulator notes that the RFID technology itself was approved in 2012. Presumably, the technology developers needed to propose in the market this solution for a number of years before they obtained their first client, Otsuka Pharmaceutical Co.

This video clip first came to my attention in December 2021, during which month I and many others were disabused of our complacency by the medical apartheid system which had gathered steam since the outbreak of the covid hysteria in January 2020.

[0] https://en.wikipedia.org/wiki/Albert_Bourla

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-pill-sensor-digitally-tracks-if-patients-have-ingested-their-medication

[2] USPTO 8115618